Jazz, Granules Pact Blocks Copy of Narcolepsy Drug Into 2037

Jazz Pharmaceuticals Plc and Granules India Ltd. agreed to a deal blocking Granules’ proposed generic version of the sleep drug Xywav for more than a decade, based on FDA-listed patent expirations.

The consent judgment, which Judge Stanley R. Chesler approved Thursday in the US District Court for the District of New Jersey, dismissed all claims with prejudice and includes an injunction barring Granules from launching its Xywav copy until Jazz’s 14 asserted patents expire, “unless and to the extent otherwise specifically authorized by Jazz.”

The latest expiration among those is in September 2037, according to Xywav’s entry in the ...